文献速递糖尿病肥胖与代谢综合征

司美格鲁肽、恩格列净或其联合治疗启动后DIAL2预测心血管风险的两年轨迹:DIAL-STEP研究

Two‐Year Trajectories of DIAL2‐Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL‐STEP Study
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-10

这项回顾性队列纳入332例无既往心血管疾病的成人,分别接受口服司美格鲁肽、恩格列净或联合治疗并随访24个月。随访期间血糖、收缩压、总胆固醇和体重改善,DIAL2预测的HIGH类别比例总体稳定,连续风险估计随危险因素和年龄变化;重复DIAL2及其分解不能确立心血管事件减少或治疗策略优劣。

要点

  • 24个月配对变化:HbA1c下降1.13个百分点,收缩压下降7.64 mmHg,总胆固醇下降20.28 mg/dL,体重下降3.91 kg。
  • DIAL2预测的HIGH类别(计算1年风险≥3%)患病率为24.6%、23.2%和23.7%,无时间×治疗交互作用(p=0.731)。
  • 连续风险的交互作用显著(p=0.002;人口学-时间校正后p=0.006);作者指出重复DIAL2不能确立心血管事件减少或治疗策略优劣。

核心结论

  • 随访期间血糖和若干其他可测危险因素改善,DIAL2分类状态总体稳定,而连续估计随危险因素变化和实际年龄而变化。
  • 重复DIAL2及其解释性分解不能确立心血管事件减少或某一治疗策略的优越性。

研究设计与样本

  • 回顾性队列研究,纳入332例无既往心血管疾病的成人,其中司美格鲁肽139例、恩格列净106例、联合治疗87例。
  • 主要终点为研究者定义的HIGH类别(计算1年风险≥3%),连续风险为次要终点;采用广义估计方程和线性混合模型评估轨迹。
  • 敏感性模型加入基线年龄、性别及其时间交互作用或基线预测风险;年龄固定和Shapley计算为探索性分析。

主要发现

  • 24个月配对变化包括HbA1c −1.13个百分点(95% CI:−1.27至−1.00)、收缩压 −7.64 mmHg(−9.48至−5.79)、总胆固醇 −20.28 mg/dL(−23.84至−16.73)和体重 −3.91 kg(−4.40至−3.41)。
  • 标准DIAL2在各访视点分别对329、327和325名参与者有效。
  • HIGH患病率为24.6%、23.2%和23.7%,无时间×治疗交互作用(p=0.731)。
  • 连续风险的交互作用显著(p=0.002;人口学-时间校正后p=0.006)。
  • 在324例完整病例中,标准预测风险从2.172%变为2.052%(相对变化−5.5%);年龄固定后24个月为1.777%(−18.2%)。

关键数值与推荐

  • HIGH类别定义为研究者定义的计算1年风险≥3%。
  • 24个月配对变化:HbA1c −1.13个百分点(95% CI:−1.27至−1.00)、收缩压 −7.64 mmHg(−9.48至−5.79)、总胆固醇 −20.28 mg/dL(−23.84至−16.73)、体重 −3.91 kg(−4.40至−3.41)。
  • HIGH患病率:24.6%、23.2%和23.7%,无时间×治疗交互作用(p=0.731)。
  • 连续风险交互作用:p=0.002;人口学-时间校正后p=0.006。
  • 完整病例(324例)标准预测风险从2.172%变为2.052%(相对变化−5.5%);年龄固定后24个月为1.777%(−18.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To describe observed clinical changes and trajectories of DIAL2-predicted cardiovascular risk during 24 months of oral semaglutide, empagliflozin or combination treatment. Materials and Methods This retrospective cohort included 332 adults without prior cardiovascular disease (semaglutide, 139; empagliflozin, 106; combination, 87). The primary endpoint was the investigator-defined HIGH category (calculated 1-year risk ≥ 3%); continuous risk was secondary. Generalized estimating equations and linear mixed models assessed trajectories. Sensitivity models added baseline age, sex and their time interactions or baseline predicted risk. Age-fixed and Shapley calculations were exploratory. Results Paired 24-month changes included HbA1c −1.13 percentage points (95% CI: −1.27 to −1.00), systolic blood pressure −7.64 mmHg (−9.48 to −5.79), total cholesterol −20.28 mg/dL (−23.84 to −16.73) and weight −3.91 kg (−4.40 to −3.41). Standard DIAL2 was valid for 329, 327 and 325 participants across visits. HIGH prevalence was 24.6%, 23.2% and 23.7%, without a time-by-treatment interaction (p = 0.731). The continuous-risk interaction was significant (p = 0.002; demographic-time-adjusted p = 0.006). In 324 complete cases, standard predicted risk changed from 2.172% to 2.052% (relative change −5.5%); holding age fixed yielded 1.777% at 24 months (−18.2%). These relative changes concern calculated probabilities. Conclusions Glycaemia and several other measured risk factors improved during follow-up. Categorical DIAL2 status remained broadly stable, while continuous estimates varied with risk-factor changes and chronological age. Repeated DIAL2 and its explanatory decompositions do not establish fewer cardiovascular events or superiority of a treatment strategy.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Two‐Year Trajectories of DIAL2‐Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL‐STEP Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。